THÔNG TIN TÀI LIỆU
7 Gillette PC, Nihill MR, Singer DB Electrophysiological mechanism for the short PR interval in Pompe's disease Am J Dis Child 1974;128:622–626 Buckley BH, Hutchins GM Pompe's disease presenting as hypertrophic cardiomyopathy with Wolff–parkinson–white syndrome Am Heart J 1978;96:246–252 Kishnani PS, Corzo D, Nicolino M, et al Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset pompe disease Neurology 2007;68(2):99–109 10 Chien YH, Lee NC, Thurberg BL, et al Pompe disease in infants: improving the prognosis by newborn screening nd early treatment Pediatrics 2009;124(6):e1116–e1125 11 Nishino I Autophagic vacuolar myopathy Semin Pediatr Neurol 2006;13(2):90–95 12 Labrune P, Huguet P, Odieure M Cardiomyopathy in glycogen storage disease type III: clinical and echographic study of 18 patients Pediatr Cardiol 1991;12:161–163 13 Dagli A, Sentner CP, Weinstein DA, et al Glycogen storage disease type III Pagon RA, Adam MP, Ardinger HH GeneReviews [Internet] University of Washington: Seattle (WA); 2010 [Seattle; 1993-2017; [Updated 2016 Dec 29] 14 Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy Ann Intern Med 1992;116(11):896–900 15 Sentner CP, Hoogeveen IJ, Weinstein DA, et al Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome J Inherit Metab Dis 2016;39(5):697– 704 16 Carvalho JS, Matthews EE, Leonard JV, Deanfield J Cardiomyopathy of glycogen storage disease type III Heart Vessels 1993;8(3):155–159 17 Lee PJ, Deanfield JE, Burch M, et al Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III Am J Cardiol 1997;79(6):834–838 18 Servidei S, Riepe RE, Langston C, et al Severe cardiopathy in branching enzyme deficiency J Pediatr 1987;111(1):51–56 19 Tang TT, Segura AD, Chen YT, et al Neonatal hypotonia and cardiomyopathy secondary to type IV glycogenosis Acta Neuropathol (Berl) 1994;87(5):531–536 20 Nase S, Kunze KP, Sigmund M, et al A new variant of type IV glycogenosis with primary cardiac manifestation and complete branching enzyme deficiency In vivo detection by heart muscle biopsy Eur Heart J 1995;16(11):1698– 1704 21 Magoulas PL, El-Hattab AW Glycogen storage disease type IV Pagon RA, Adam MP, Ardinger HH, et al GeneReviews University of Washington,: Seattle (WA); 2013 [Seattle; 19932017] 22 Scalco RS, Morrow JM, Booth S, et al Misdiagnosis is an important factor for diagnostic delay in McArdle disease Neuromuscul Disord 2017 [pii: S09608966(17)30056-1] 23 Milstein JM, Herron TM, Haas JE Fatal infantile muscle phosphorylase deificiency J Child Neurol 1989;4(3):186–188 24 Miranda AF, Nette EG, Hartlage PL, DiMauro S Phosphorylase isoenzymes in normal and myophosphorylase-deficient human heart Neurology 1979;29(11):1538–1541 25 Salter RH The muscle glycogenoses Lancet 1968;1:1301–1304 26 Servidei S, Metlay LA, Chodosh J, Di Mavro S
Ngày đăng: 22/10/2022, 12:52
Xem thêm: